Biotricity announces patent filing for Bioheart device

Biotricity announced its patent filing for the company’s Bioheart device. Bioheart, regarded as one of the most innovative wearable heart monitoring solutions and recognized as one of TIME Magazine’s Best Inventions of 2022 stands as a “game changer” in the industries of personal heart and remote lifestyle monitoring. This patent safeguards Bioheart’s exclusive 3-view dry-contact technology, advanced sensor system, unique design, and compact form factor – a combination that’s never been seen in the consumer market. This patent application reaffirms Biotricity’s commitment to enhancing its Intellectual Property portfolio, protecting its innovations while strengthening its position as a leader in personal lifestyle and healthcare innovation. Dr. Waqaas Al-Siddiq, CEO of Biotricity, commented on the patent filing, stating, “It is with great pride that we announce the filing of our second Biotricity patent in just a month. The Bioheart patent filing reflects our focused commitment to advancing our broader strategy to continuously strengthen our IP, trade secrets, and FDA 510(k) portfolios. This not only helps solidify our leadership in the industry but also ensures that our competitive advantages remain at the forefront of the market.”